Neurocrine Biosciences, Inc. (NBIX) Position Increased by California Public Employees Retirement System

California Public Employees Retirement System lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 181,900 shares of the company’s stock after buying an additional 2,600 shares during the period. California Public Employees Retirement System owned about 0.21% of Neurocrine Biosciences worth $11,147,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company boosted its stake in Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares during the period. Comerica Bank acquired a new position in Neurocrine Biosciences in the 3rd quarter worth $210,000. Trexquant Investment LP acquired a new position in Neurocrine Biosciences in the 3rd quarter worth $246,000. World Asset Management Inc acquired a new position in Neurocrine Biosciences in the 3rd quarter worth $246,000. Finally, Stifel Financial Corp acquired a new position in Neurocrine Biosciences in the 3rd quarter worth $246,000.

In related news, insider Christopher Flint Obrien sold 6,925 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $61.04, for a total value of $422,702.00. Following the completion of the sale, the insider now directly owns 55,898 shares in the company, valued at approximately $3,412,013.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kyle Gano sold 24,818 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total transaction of $1,763,318.90. Following the completion of the sale, the insider now owns 84,596 shares of the company’s stock, valued at $6,010,545.80. The disclosure for this sale can be found here. Insiders sold a total of 90,877 shares of company stock valued at $6,568,617 over the last quarter. 4.80% of the stock is currently owned by company insiders.

A number of equities analysts recently weighed in on NBIX shares. Robert W. Baird reaffirmed an “outperform” rating and issued a $66.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, September 21st. Oppenheimer set a $85.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Jefferies Group reaffirmed a “buy” rating and issued a $69.00 target price (up from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. Leerink Swann restated an “outperform” rating and set a $83.00 price objective (up from $72.00) on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Finally, Barclays increased their price objective on shares of Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, November 2nd. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $78.88.

Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $73.74 on Thursday. Neurocrine Biosciences, Inc. has a one year low of $37.35 and a one year high of $75.98. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. The company has a market cap of $6,530.00, a PE ratio of -33.22 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.36. Neurocrine Biosciences had a negative net margin of 18.31% and a negative return on equity of 12.88%. The company had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same period in the prior year, the business posted ($0.43) EPS. research analysts anticipate that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.com-unik.info/2017/12/28/neurocrine-biosciences-inc-nbix-position-increased-by-california-public-employees-retirement-system.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit